Table 1 Comparison of the characteristics of research units between prostate cancer and control groups
From: Possible role of HPV/EBV coinfection in anoikis resistance and development in prostate cancer
Characteristics | Prostate Cancer (67) | Control (40) | P | OR (95% CI) | |
|---|---|---|---|---|---|
Age (Year) | 52.7 ± 12.2 | 55.6 ± 9.9 | 0.19 | 0.95 (0.9–1.02) | |
HPV positive samples | Presence | 31.3% (n = 21) | 15% (n = 6) | 0.060 | 1.84 (0.08–0.6) |
EBV positive samples | Presence | 49.3% (n = 33) | 40% (n = 16) | 0.353 | 1.06 (0.8–1.39) |
Mono HPV-infection | 16.4% (11) | 7.5% (n = 3) | 0.289 | 1.06 (0.26–6.5) | |
Co-infection (EBV&HPV) | 14.9% (n = 10) | 7.5% (n = 3) | 0.314 | 2.9 (0.18–45.2) | |
Mono EBV-infection | 34.3% (n = 23) | 42.5% (n = 17) | 0.48 | 0.58 (0.17–2.6) | |
Non-EBV and Non-HPV samples | 34.3% (n = 23) | 42.5% (n = 17) | 0.48 | NA | |
HPV Genotype | 6 | 4.8% (1/21) | 0 | 0.248 | 1.23 (0.51–4.42) |
11 | 0 | 16.7% (1/6) | |||
16 | 47.6% (10/21) | 50% (3/6) | |||
18 | 33.3% (7/21) | 33.33% (2/6) | |||
33 | 3 (15.8%) | 0 | |||
EBV Genotype | 1 | 9.09% (3/33) | 0 | 0.105 | 0.55 (0.077–3.71) |
2 | 90.9% (30/33) | 100% (20/20) | |||
Type of Cancer | Acinar adenocarcinoma | 40 (59.7%) | – | NA | NA |
Ductal Adenocarcinoma | 21 (31.34%) | – | NA | NA | |
Squamous cell cancer | 6 (8.95%) | – | NA | NA | |
Stage of Cancer | I | 4 (5.9%) | – | NA | NA |
IIA | 9 (13.4%) | – | NA | NA | |
IIB | 9 (13.4%) | – | NA | NA | |
IIC | 5 (7.4%) | – | NA | NA | |
IIIA | 2 (2.98%) | – | NA | NA | |
IIIB | 10 (14.9%) | – | NA | NA | |
IIIC | 6 (8.9%) | – | NA | NA | |
IVA | 12 (17.9%) | – | NA | NA | |
IVB | 10 (14.9%) | – | NA | NA | |